Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
0 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
3 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
6 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
9 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
12 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
15 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
18 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
21 months |
|
Primary |
Seroprevalence of SARS-Cov-2 antibodies (positive antibody test) |
Cumulative presence of SARS-CoV-2 antibodies in plasma. |
24 months |
|
Primary |
Change in levels of SARS-Cov-2 antibodies (antibody titers) |
Change in titers of SARS-CoV-2 antibodies in plasma over time. |
0-24 months |
|
Secondary |
Cellular response to SARS-Cov-2 (Th4 and Th8 levels) |
PBMC specific responses, measured in PCR/serology positive patients. |
3 months |
|
Secondary |
Cellular response to SARS-Cov-2 (Th4 and Th8 levels) |
PBMC specific responses, measured in PCR/serology positive patients. |
12 months |
|
Secondary |
Cellular response to SARS-Cov-2 (Th4 and Th8 levels) |
PBMC specific responses, measured in PCR/serology positive patients. |
24 months |
|
Secondary |
Change in cellular response to SARS-Cov-2 (Th4 and Th8 levels) |
Change in PBMC specific responses over time |
0-24 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
0 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
3 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
6 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
9 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
12 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
15 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
18 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
21 months |
|
Secondary |
Symptoms and hospitalisations (electronic questionnaire) |
Self-reported symptoms (WHO list of common COVID-19 symptoms) and hospitalisations during the past 3 months. |
24 months |
|